Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus

by Calvo Pinilla, Eva María, Navasa, N., Anguita, J., Ortego Alonso, Francisco Javier
Published 2012

Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift Valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination

by Lorenzo Alguacil, Gema, López-Gil, E., Ortego Alonso, Francisco Javier, Brun Torres, Alejandro
Published 2018

Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection

by Calvo Pinilla, Eva María, Rodríguez-Calvo, T., Sevilla Hidalgo, Noemi, Ortego Alonso, Francisco Javier
Published 2009

The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed V...

by Calvo Pinilla, Eva María, Gubbins, S., Mertens, P., Ortego Alonso, Francisco Javier, Castillo-Olivares, J.
Published 2018

Establishment of a bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor

by Calvo Pinilla, Eva María, Rodríguez-Calvo, T., Anguita, J., Sevilla Hidalgo, Noemi, Ortego Alonso, Francisco Javier
Published 2009

Defeating Bluetongue virus New approaches in the development of multiserotype vaccines

by Marín-López, A., Barriales, D., Moreno Fernández, Sandra, Ortego Alonso, Francisco Javier, Calvo Pinilla, Eva María
Published 2016

Recombinant vaccines against bluetongue virus

by Calvo Pinilla, Eva María, Castillo-Olivares, J., Jabbar, T., Ortego Alonso, Francisco Javier, De la Poza, F., Marín-López, A.
Published 2014

Pathological characterization of IFNAR(-/-) mice infected with bluetongue virus serotype 4

by Marín-López, A., Bermúdez, R., Calvo Pinilla, Eva María, Moreno Fernández, Sandra, Brun Torres, Alejandro, Ortego Alonso, Francisco Javier
Published 2016

Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48...

by Calvo Pinilla, Eva María, De La Poza, F., Gubbins, S., Mertens, P. P. C., Ortego Alonso, Francisco Javier, Castillo-Olivares, J.
Published 2015

Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that con...

by Calvo Pinilla, Eva María, de la Poza, F., Gubbins, S., Mertens, P. P. C., Ortego Alonso, Francisco Javier, Castillo-Olivares, J.
Published 2014

CD8 T cell responses to an immunodominant epitope within the nonstructural protein NS1 provide wide immunoprotection against bluetongue virus in IFNAR-/- mice

by Marín-López, A., Calvo Pinilla, Eva María, Barriales, D., Lorenzo Alguacil, Gema, Brun Torres, Alejandro, Anguita, J., Ortego Alonso, Francisco Javier
Published 2018

Immunization of knock-out α/β interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen

by Franceschi, V., Capocefalo, A., Calvo Pinilla, Eva María, Redaelli, M., Mucignat-Caretta, C., Mertens, P., Ortego Alonso, Francisco Javier, Donofrio, G.
Published 2011

A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model

by Aksular, M., Calvo Pinilla, Eva María, Marín-López, A., Ortego Alonso, Francisco Javier, Chambers, A. C., King, L. A., Castillo-Olivares, J.
Published 2018

Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(−/−) mice conferring protection against serotypes 1 and 4 of bluetongue virus

by Marín-López, A., Calvo Pinilla, Eva María, Barriales, D., Lorenzo Alguacil, Gema, Benavente, J., Brun Torres, Alejandro, Martínez-Costas, J. M., Ortego Alonso, Francisco Javier
Published 2017

A Modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR 2/2 mouse model

by Castillo-Olivares, J., Calvo Pinilla, Eva María, Casanova, I., Bachanek-Bankowska, K., Chiam, R., Maan, S., Nieto, J. M., Ortego Alonso, Francisco Javier, Mertens, P. P. C.
Published 2011

VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(-/-) mice

by Marín-López, A., Otero-Romero, I., De La Poza, F., Menaya-Vargas, R., Calvo Pinilla, Eva María, Benavente, J., Martínez-Costas, J. M., Ortego Alonso, Francisco Javier
Published 2014

Protection of IFNAR (-/-) mice against Bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2

by Jabbar, T. K., Calvo Pinilla, Eva María, Mateos, F., Gubbins, S., Bin-Tarif, A., Bachanek-Bankowska, K., Alpar, O., Ortego Alonso, Francisco Javier, Takamatsu, H. H., Mertens, P. P. C., Castillo-Olivares, J.
Published 2013

Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems

by Brun Torres, Alejandro, Albina, E., Barret, T., Chapman, D. A. G., Czub, M., Dixon, L. K., Keil, G. M., Klonjkowski, B., Le Potier, M. F., Libeau, G., Ortego Alonso, Francisco Javier, Richardson, J., Takamatsu, H. H.
Published 2008